Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05481814

CPX in Paradoxical Low Flow Aortic Stenosis

The Role of Cardiopulmonary Stress Testing in Diagnostic Evaluation of Paradoxical Low Gradient Aortic Valve Stenosis

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Henry Ford Health System · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Severe aortic stenosis is a condition with poor life expectancy once it becomes symptomatic. There are no prospective studies illustrating the utility of cardiopulmonary stress (CPX) testing in diagnosing and prognosticating patients with paradoxically low gradient and low flow severe aortic stenosis. We aim to prospectively investigate the utility of CPX in this patient population with the hypothesis that utilizing CPX parameters would better identify higher risk patients warranting further evaluation and possibly intervention sooner.

Detailed description

This will be a prospective crossectional, longitudinal study recruiting patients by invitation with paradoxical low flow low gradient severe aortic stenosis. Patients with PLFLG AS will have been identified in other studies and these patients will be approached for enrollment in the study. Patients deemed appropriate for enrollment will undergo recumbent bicycle stress testing with concomitant measure of gas exchange. The bicycle will be at 30 degrees with initiation of minimal resistance for 3 minutes, followed by an increase in work-rate of 25 watts every two minutes until the patient reaches a sign/symptom-limited maximum exertion or test limiting symptoms develop. Charts will be reviewed for baseline medical conditions and demographics. CPX protocol will be standard HFH protocol supervised by exercise physiologist. The first phase of the study will be investigating if these asymptomatic patients will be reclassified to symptomatic as defined by reduced V02 Max. The second phase will be following these patients for long term adverse events and if V02 max correlates with a higher risk.

Conditions

Timeline

Start date
2017-09-30
Primary completion
2018-04-01
Completion
2022-07-01
First posted
2022-08-01
Last updated
2022-08-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05481814. Inclusion in this directory is not an endorsement.